BAJAJ BROKING

Notification close image
No new Notification messages
card image
Travel Food Services IPO is Open!
Apply for the Travel Food Services IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Asston Pharmaceuticals IPO: Things Smart Investors Need to Know

Asston Pharmaceuticals Limited, established in 2019, is engaged in the manufacturing and export of pharmaceutical and nutraceutical products. With operations spanning across various Asian and African markets, the company offers a broad range of formulations including tablets, capsules, syrups, ointments, gels, and sachets. It focuses on therapeutic categories such as antibiotics, antifungals, analgesics, vitamins, and mineral supplements. Asston operates through both direct sales and contract manufacturing, following a principle-to-principle model with marketers. The company has obtained FDA certifications from central and state authorities and is accredited by NQA, ensuring adherence to recognised quality standards.

With a team of 46 permanent and 6 contractual employees, the company also partners with WHO-GMP certified manufacturers and FDA-approved labs. This setup helps maintain consistent product quality from production to export. Its portfolio includes commonly used formulations like Albendazole USP 400 mg, Diclofenac 100 mg, Ibuprofen-Paracetamol combinations, and Ferrovit Syrup, catering to a wide range of healthcare needs.

For more details, visit the Asston Pharmaceuticals IPO page.

Asston Pharmaceuticals IPO Details and Objectives

Details

Information

IPO Date

July 9, 2025 to July 11, 2025

Issue Size

22,41,000 shares

(aggregating up to ₹27.56 Cr)

Price Band

₹115 to ₹123 per share

Lot Size

1000 shares

Listing At

BSE SME

Market Maker

JSK Securities and Services Private Limited

Purpose of the IPO

  • Carry out the Offer for Sale

  • Achieve the benefits of listing the Equity Shares on the Stock Exchanges

Timeline of Asston Pharmaceuticals IPO

Event

Date

IPO Open Date

Wed, Jul 9, 2025

IPO Close Date

Fri, Jul 11, 2025

Tentative Allotment

Mon, Jul 14, 2025

Initiation of Refunds

Tue, Jul 15, 2025

Credit of Shares to Demat

Tue, Jul 15, 2025

Tentative Listing Date

Wed, Jul 16, 2025

Cut-off time for UPI mandate confirmation

5 PM on July 11, 2025

Pricing & Lot Size of Asston Pharmaceuticals IPO

Price Band for the IPO

  • ₹115 to ₹123 per share

Minimum Lot Size and Application Details

Application

Lots

Shares

Amount

Individual investors (Retail) (Min)

2

2,000

₹2,46,000

Individual investors (Retail) (Max)

2

2,000

₹2,46,000

S-HNI (Min)

3

3,000

₹3,69,000

S-HNI (Max)

8

8,000

₹9,84,000

B-HNI (Min)

9

9,000

₹11,07,000

How to Apply for the Asston Pharmaceuticals IPO?

Online Application Process

  • Log in to Your Trading Account
    Access your trading account through your broker’s platform.

  • Navigate to the IPO Section
    Go to the IPO section to view active IPO listings.

  • Select Asston Pharmaceuticals IPO
    Find "Asston Pharmaceuticals IPO" and click on the ‘Apply’ button.

  • Enter Application Details
    Specify the number of lots (minimum lot size: 1000 shares) and the bid price within the range of ₹115 to ₹123 per share.

  • Provide Your UPI ID
    Enter your UPI ID for payment authorization. Ensure that sufficient funds are available in your linked account.

  • Review and Submit
    Verify all the details entered before submitting the application. Approve the UPI mandate before 5 PM on July 11, 2025, to complete your application process.

Financial Health and Performance

Key Financial Metrics

  • Total Assets: Grew from ₹13.69 crore in FY23 to ₹31.83 crore as of May 2025.

  • Revenue: Reached ₹6.21 crore in FY25.

  • Profit After Tax (PAT): Stood at ₹1.32 crore for May 2025.

  • Net Worth: Recorded at ₹12.04 crore in FY25.

  • Reserves and Surplus: Recorded at ₹5.77 crore (May 2025), growing steadily over the years.

  • EBITDA: Stood at ₹1.93 crore in May 2025.

Recent Performance and Growth Prospects

  • The company has witnessed a steady increase in its total assets, reflecting its expansion efforts and operational growth.

  • Its revenue generation has shown a consistent upward trend, indicating a growing demand for its products in domestic and international markets.

  • Profitability has improved over time, pointing to effective cost management and operational efficiency.

  • The company’s net worth has strengthened, showcasing improved financial health and stability.

  • Reserves and surplus have grown gradually, supporting reinvestment and future expansion strategies.

  • Operational performance, as seen in earnings before interest, tax, depreciation, and amortisation, suggests a focus on improving margins and sustainable profitability.

Investment Risks and Opportunities

Potential Risks of Investing in the IPO

  • The company’s scale of operations and workforce is relatively modest, which may limit its ability to manage large-scale expansion or face industry disruptions.

  • Heavy reliance on third-party manufacturers, even if certified, could affect quality control, timelines, or compliance if not closely monitored.

Opportunities and Growth Potential

  • Presence across Asian and African markets, along with a broad therapeutic product range, positions the company to cater to growing international healthcare needs.

  • Collaborations with certified manufacturers and compliance with recognised quality standards provide a foundation for potential market expansion and client acquisition.

Key Performance Indicator (KPI)

KPI

Values

ROE

50.56%

ROCE

51.25%

Debt/Equity

0.68

RoNW

40.36%

PAT Margin

17.27%

EBITDA Margin

24.60%

Price to Book Value

12.07

Asston Pharmaceuticals IPO Registrar & Lead Managers

Registrar

Lead Manager(s)

Maashitla Securities Private Limited

Sobhagya Capital Options Ltd

Company Address of Asston Pharmaceuticals Ltd

Asston Pharmaceuticals Ltd.

4th Floor, Office No. A-431 Balaji Bhavan,

Plot No 42A Sector-11 CBD Belapur,

Navi Mumbai, Thane

Navi Mumbai, Maharashtra, 400614

Phone: +91 22 49731411

Email: info@asstonpharmaceuticals.com

Website: http://www.asstonpharmaceuticals.com/

Conclusion

Asston Pharmaceuticals Limited operates in the pharmaceutical and nutraceutical manufacturing space with a focus on exports to Asian and African markets. The company’s offerings cover a wide range of therapeutic categories, and its business model includes both direct sales and contract manufacturing. Certifications from recognised regulatory bodies support its compliance with industry standards.

The IPO is aimed at carrying out an offer for sale and achieving the benefits of listing on the stock exchange. With a defined product portfolio, operational structure, and export presence, the company maintains its focus on consistent production and market engagement across geographies.

Interested in more opportunities? Check out our Upcoming IPO section for new listings, and don’t forget to check your IPO allotment status for Asston Pharmaceuticals IPO.

Share this article: 

Frequently Asked Questions

No result found

search icon

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.2 App Rating

icon-with-text

4 Languages

icon-with-text

₹5600+ Cr MTF Book

icon-with-text
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|